Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin

Journal of the National Cancer Institute

Volumn 95, Issue 14, 2003, Pages 1053-1061

  Chen, Xiaoxin ^a   Li, Ning ^a   Wang, Su ^a   Hong, Jungil ^a   Jiao, Xiaolong ^b   Krasna, Mark J ^b   Beer, David G ^c   Yang, Chung S ^a  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BESTATIN; ENZYME INHIBITOR; LEUKOTRIENE A4 HYDROLASE; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; EPOXIDE HYDROLASE; LEUCINE; LEUKOTRIENE A4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER TISSUE; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLUMNAR EPITHELIUM; CONTROLLED STUDY; DYSPLASIA; ENZYME INHIBITION; ENZYME SYNTHESIS; ESOPHAGUS CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RAT; SQUAMOUS EPITHELIUM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TISSUE LEVEL; TISSUE SECTION; WESTERN BLOTTING; ADENOCARCINOMA; ANASTOMOSIS; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DUODENUM; ENZYMOLOGY; ESOPHAGUS; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; INCIDENCE; INFLAMMATION; METABOLISM; METHODOLOGY; STOMACH; TREATMENT OUTCOME; UPREGULATION;

ADENOCARCINOMA; ANASTOMOSIS, SURGICAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; DUODENUM; EPOXIDE HYDROLASES; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; INFLAMMATION; LEUCINE; LEUKOTRIENE A4; RATS; STOMACH; TREATMENT OUTCOME; UP-REGULATION;

EID: 0043095584     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.14.1053     Document Type: Article

References (77)

1. Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 2002;95: 2096-102.
2. Farrow DC, Vaughan TL. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 1996;7:322-7.
3. Goldstein SR, Yang GY, Chen X, Curtis SK, Yang CS. Studies of iron deposits, inducible nitric oxide synthase and nitrotyrosine in a rat model for esophageal adenocarcinoma. Carcinogenesis 1998;19:1445-9.
4. Chen X, Ding W, Yang GY, Bondoc F, Yang CS. Oxidative damage in an esophagoduodenal anastomosis (EDA) rat model. Carcinogenesis 2000;21: 257-63.
5. Chen X, Yang GY, Ding W, Bondoc F, Curtis SK, Yang CS. An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis 1999;20: 1801-7.
6. Chen X, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis 2001;22:1119-29.
7. Steele VE, Hawk ET, Viner JL, Luber RA. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 2003;523-524:137-44.
8. Hong SH, Avis I, Vos MD, Martinez A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 1999;59:2223-8.
9. Chiu CH, McEntee MF, Whelan J. Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+) mice. Prostaglandins Leukot Essent Fatty Acids 2000;62:269-75.
10. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-34.
11. Chen X, Li N, Wang S, Hong J, Fang M, Yousselfson J, et al. Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and a-difluoromethylornithine on tumorigenesis in a rat surgical model. Carcinogenesis 2002;23: 2095-102.
12. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118:487-96.
13. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60:5767-72.
14. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002;122:1101-12.
15. Marleau S, Fruteau de Laclos B, Sanchez AB, Poubelle PE, Borgeat P. Role of 5-lipoxygenase products in the local accumulation of neutrophils in dermal inflammation in the rabbit. J Immunol 1999;163:3449-58.
16. Goulet JL, Snouwaert JN, Latour AM, Coffman TM, Koller BH. Altered inflammatory response in leukotriene-deficient mice. Proc Natl Acad Sci U S A 1994;91:12852-6.
17. Byrum RS, Goulet JL, Griffiths RJ, Koller BH. Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J Exp Med 1997;185:1065-75.
18. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun 1997;235:418-23.
19. Rioux N, Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis 1998;19:1393-400.
20. Moody TW, Leyton J, Martinez A, Hong S, Malkinson A, Mulshine JL. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res 1998;24:617-28.
21. Jiang H, Yamamoto S, Kato R. Inhibition of two-stage skin carcinogenesis as well as complete skin carcinogenesis by oral administration of TMK688, a potent lipoxygenase inhibitor. Carcinogenesis 1994;15:807-12.
22. Castonguay A, Rioux N, Duperron C, Jalbert G. Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis. Exp Lung Res 1998;24: 605-15.
23. Marcinkiewicz M, Sarosiek J, Edmunds M, Scheurich J, Weiss P, McCallum RW. Monophasic luminal release of PGE2 in patients with reflux esophagitis under the impact of acid and acid/pepsin solutions. J Clin Gastroenterol 1995;21:268-74.
24. Triadafilopoulos G, Kaczynska M, Iwane M. Esophageal mucosal eicosanoids in gastroesophageal reflux disease and Barrett's esophagus. Am J Gastroenterol 1996;91:65-74.
25. Chen X, Ding Y, Liu CG, Mikhail S, Yang CS. Overexpression of glucose-regulated protein 94 (Grp94) in esophageal adenocarcinomas of a rat surgical model and humans. Carcinogenesis 2002;23:123-30.
26. Bronstein I, Voyta JC, Murphy OJ, Bresnick L, Kricka LJ. Improved chemiluminescent Western blotting procedure. Biotechniques 1992;12: 748-53.
27. Makita N, Funk CD, Imai E, Hoover RL, Badr KF. Molecular cloning and functional expression of rat leukotriene A4 hydrolase using the polymerase chain reaction. FEBS Lett 1992;299:273-7.
28. Lewin KJ, Appelman HD. Barrett's esophagus, columnar dysplasia, and adenocarcinoma of the esophagus. In: Lewin KJ, Appelman HD, editors. Tumors of the esophagus and stomach. Washington (DC): Armed Forces Institute of Pathology Press; 1995. p. 99-144.
29. Goldstein SR, Yang GY, Curtis SK, Reuhl KR, Liu BC, Mirvish SS, et al. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 1997;18: 2265-70.
30. Orning L, Krivi G, Fitzpatrick FA. Leukotriene A4 hydrolase: inhibition by bestatin and intrinsic aminopeptidase activity establish its functional resemblance to metallohydrolase enzymes. J Biol Chem 1991;266:1375-8.
31. Haeggstrom JZ, Kull F, Rudberg PC, Tholander F, Thunnissen MM. Leukotriene A4 hydrolase. Prostaglandins Other Lipid Mediat 2002;68-69: 495-510.
32. Byrum RS, Goulet JL, Snouwaert JN, Griffiths RJ, Koller BH. Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice. J Immunol 1999;163:6810-9.
33. Crooks SW, Stockley RA. Leukotriene B4. Int J Biochem Cell Biol 1998; 30:173-8.
34. Dahlen SE. Leukotriene receptors. Clin Rev Allergy Immunol 1999;17: 179-91.
35. Yokomizo T, Izumi T, Shimizu T. Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys 2001;385:231-41.
36. Muskardin DT, Voelkel NF, Fitzpatrick FA. Modulation of pulmonary leukotriene formation and perfusion pressure by bestatin, an inhibitor of leukotriene A4 hydrolase. Biochem Pharmacol 1994;48:131-7.
37. Tsuji F, Oki K, Fujisawa K, Okahara A, Horiuchi M, Mita S. Involvement of leukotriene B4 in arthritis models. Life Sci 1999;PL64:51-6.
38. Penning TD. Inhibitiors of leukotriene A4 (LTA4) hydrolase as potential anti-inflammatory agents. Curr Pharm Des 2001;7:163-79.
39. Dreyling KW, Hoppe U, Peskar BA, Morgenroth K, Kozuschek W, Peskar BM. Leukotriene synthesis by human gastrointestinal tissues. Biochim Biophys Acta 1986;878:184-93.
40. Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, Rigas B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta 1996;1300:240-6.
41. Qiao L, Kozoni V, Tsioulias GJ, Koutsos MI, Hanif R, Shiff SJ, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1995;1258:215-23.
42. Ohd JF, Wikstrom K, Sjolander A. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology 2000;119:1007-18.
43. Woo CH, You HJ, Cho SH, Eom YW, Chun JS, Yoo YJ, et al. Leukotriene B4 stimulates Rac-ERK cascade to generate reactive oxygen species that mediates chemotaxis. J Biol Chem 2002;277:8572-8.
44. Steiner DR, Gonzalez NC, Wood JG. Leukotriene B(4) promotes reactive oxidant generation and leukocyte adherence during acute hypoxia. J Appl Physiol 2001;91:1160-7.
45. Stockton RA, Jacobson BS. Modulation of cell-substrate adhesion by arachidonic acid: lipoxygenase regulates cell spreading and ERK1/2-inducible cyclooxygenase regulates cell migration in NIH-3T3 fibroblasts. Mol Biol Cell 2001;12:1937-56.
46. Bauer RW, van der Kerhof PC, de Grood RM. Epidermal hyperproliferation following the induction of microabscesses by leukotriene B4. Br J Dermatol 1986;114:409-12.
47. Ruzicka T, Burg G. Effects of chronic intracutaneous administration of arachidonic acid and its metabolites. Induction of leukocytoclastic vasculitis by leukotriene B4 and 12-hydroxyeicosatetraenoic acid and its prevention by prostaglandin E2. J Invest Dermatol 1987;88:120-3.
48. Tong WG, Ding XZ, Hennig R, Witt RC, Standop J, Pour PM, et al. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin Cancer Res 2002; 8:3232-42.
49. Anthonsen MW, Andersen S, Solhaug A, Johansen B. Atypical lambda/iota PKC conveys 5-lipoxygenase/leukotriene B4-mediated cross-talk between phospholipase A2s regulating NF-kappa B activation in response to tumor necrosis factor-alpha and interleukin-1beta. J Biol Chem 2001;276: 35344-51.
50. Surette ME, Krump E, Picard S, Borgeat P. Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: inhibition by adenosine A(2a) receptor agonists and crucial role of autocrine activation by leukotriene B(4). Mol Pharmacol 1999;56:1055-62.
51. Montero A, Nassar GM, Uda S, Munger KA, Badr KF. Reciprocal regulation of LTA(4) hydrolase expression in human monocytes by gamma-interferon and interleukins 4 and 13: potential relevance to leukotriene regulation in glomerular disease. Exp Nephrol 2000;8:258-65.
52. Zaitsu M, Hamasaki Y, Matsuo M, Kukita A, Tsuji K, Miyazaki M, et al. New induction of leukotriene A(4) hydrolase by interleukin-4 and interleukin-13 in human polymorphonuclear leukocytes. Blood 2000;96:601-9.
53. Iversen L, Svendsen M, Kragballe K. Cyclosporin A down-regulates the LTA4 hydrolase level in human keratinocyte cultures. Acta Derm Venereol 1996;76:424-8.
54. Munafo DA, Shindo K, Baker JR, Bigby TD. Leukotriene A4 hydrolase in human bronchoalveolar lavage fluid. J Clin Invest 1994;93:1042-50.
55. Hattori N, Fujiwara H, Maeda M, Yoshioka S, Higuchi T, Mori T, et al. Human large luteal cells in the menstrual cycle and early pregnancy express leukotriene A4 hydrolase. Mol Hum Reprod 1998;4:803-10.
56. Menegatti E, Roccatello D, Fadden K, Piccoli G, De Rosa G, Sena LM, et al. Gene expression of 5-lipoxygenase and LTA4 hydrolase in renal tissue of nephrotic syndrome patients. Clin Exp Immunol 1999;116: 347-53.
57. Ishizaka N, Nakao A, Ohishi N, Suzuki M, Aizawa T, Taguchi J, et al. Increased leukotriene A(4) hydrolase expression in the heart of angiotensin II-induced hypertensive rat. FEBS Lett 1999;463:155-9.
58. Eberhard J, Jepsen S, Tiemann M, Krause R, Acil Y, Albers HK. Leukotriene A(4)-hydrolase expression and leukotriene B(4) levels in chronic inflammation of bacterial origin: immunohistochemistry and reverse-phase high-performance liquid chromatography analysis of oral mucosal epithelium. Virchows Arch 2002;440:627-34.
59. Dias VC, Shaffer EA, Wallace JL, Parsons HG. Bile salts determine leukotriene B4 synthesis in a human intestinal cell line (CaCo-2). Dig Dis Sci 1994;39:802-8.
60. Craven PA, Pfanstiel J, DeRubertis FR. Role of reactive oxygen in bile salt stimulation of colonic epithelial proliferation. J Clin Invest 1986;77:850-9.
61. Haeggstrom JZ. Leukotriene A4 hydrolase and the committed steps in leukotriene B4 biosynthesis. Clin Rev Allergy Immunol 1999;17:111-31.
62. Ezawa K, Minato K, Dobashi K. Induction of apoptosis by ubenimex (bestatin) in human non-small-cell lung cancer cell lines. Biomed Pharmacother 1996;50:283-9.
63. Sekine K, Fujii H, Abe F, Nishikawa K. Augmentation of death ligand-induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines. Int J Cancer 2001;94:485-91.
64. Grujic M, Renko M. Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions. Cancer Lett 2002;182:113-9.
65. Ebihara K, Abe F, Yamashita T, Shibuya K, Hayashi E, Takahashi K, et al. The effect of ubenimex on N-methyl-N′-nitro-N-nitrosoguanidine-induced stomach tumor in rats. J Antibiot 1986;39:966-70.
66. Fujioka S, Kohno N, Hiwada K. Ubenimex activates the E-cadherin-mediated adhesion of a breast cancer cell line YMB-S. Jpn J Cancer Res 1995;86:368-73.
67. Abe F, Schneider M, Black PL, Talmadge JE. Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice. Cancer Immunol Immunother 1989;29:231-6.
68. Talmadge JE, Lenz BF, Pennington R, Long C, Phillips H, Schneider M, et al. Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Res 1986;46:4505-10.
69. Scornik OA, Botbol V. Bestatin as an experimental tool in mammals. Curr Drug Metab 2001;2:67-85.
70. Ishii K, Usui S, Sugimura Y, Yoshida S, Hioki T, Tatematsu M, et al. Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 2001;92:49-54.
71. Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 2002;122:376-86.
72. Mishima Y, Matsumoto-Mishima Y, Terui Y, Katsuyama M, Yamada M, Mori M, et al. Leukemic cell-surface CD13/aminopeptidase N and resistance to apoptosis mediated by endothelial cells. J Natl Cancer Inst 2002; 94:1020-8.
73. Ino K, Bierman PJ, Varney ML, Heimann DG, Kuszynski CA, Walker SA, et al. Monocyte activation by an oral immunomodulator (bestatin) in lymphoma patients following autologous bone marrow transplantation. Cancer Immunol Immunother 1996;43:206-12.
74. Jankowski JA. Barrett's metaplasia. Lancet 2000;356:2079-85.
75. Thunnissen MM, Nordlund P, Haeggstrom JZ. Crystal structure of human leukotriene A4 hydrolase, a bifunctional enzyme in inflammation. Nat Struct Biol 2001;8:131-5.
76. Rudberg PC, Tholander F, Thunnissen MM, Samuelsson B, Haeggstrom JZ. Leukotriene A4 hydrolase: selective abrogation of leukotriene B4 formation by mutation of aspartic acid 375. Proc Natl Acad Sci U S A 2002; 99:4215-20.
77. Penning TD, Russell MA, Chen BB, Chen HY, Liang CD, Mahoney MW, et al. Synthesis of potent leukotriene A(4) hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid. J Med Chem 2002;45:3482-90.